Pegylated Recombinant Human Arginase I

DB16282InvestigationalProtein Based Therapies

Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).

Mechanism: Pharmacologically active on Arginine
Curator reviewed
Also known as: Pegylated recombinant human arginase i bct-100
Code names: BCT-100 · RH-ARG1-PEG-5,000 MW

Resolves to

Compound

UNIIS3HC6XX81XCAS1433787-75-7

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Pegylated Recombinant Human Arginase I, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account